当前位置:
X-MOL 学术
›
Liver Cancer
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Liver Cancer ( IF 13.8 ) Pub Date : 2022-02-18 , DOI: 10.1159/000523702 Masatoshi Kudo 1
Liver Cancer ( IF 13.8 ) Pub Date : 2022-02-18 , DOI: 10.1159/000523702 Masatoshi Kudo 1
Affiliation
N/A
中文翻译:
Durvalumab 加 Tremelimumab:一种新的联合免疫疗法治疗不可切除的肝细胞癌
不适用
更新日期:2022-02-18
中文翻译:
Durvalumab 加 Tremelimumab:一种新的联合免疫疗法治疗不可切除的肝细胞癌
不适用